Antibody Drug Conjugates Market

Antibody Drug Conjugates Market - Size, Share,
Growth, Outlook, and Opportunity Analysis,
2018-2026
Antibody drug conjugate is a significant class of highly potent bio drugs envisioned as a broad
therapy for treatment of cancer. Unlike chemotherapy, antibody drug conjugate are proposed to mark
and kill only cancer cells. Antibody drug conjugates are compound molecules that comprise
antibodies linked to a biologically active cytotoxic drug.
Request Sample Copy of Research Report:
https://www.coherentmarketinsights.com/insight/request-sample/181
By uniting the exclusive targeting capacities of mAB with anti-cancer drugs, ADCs allow for subtle
judgment between healthy and diseased tissue. This entails that the antibody drug conjugates kill
only cancer cells and ensure that other dynamic cells are less severely affected. This exceptional
phenomenon of killing only cancer cells increase the importance of use of ADCs, which would
indirectly boost growth of the global antibody drug conjugates market.
Commercialization of 7-10 ADCs in the following decade, would lead to revenue to
surge to over US$ 10 billion over the forecast period of market
In terms of marketing, three antibody drug conjugates have received regulatory approval. The
U.S. FDA approved one of the ADC in 2001 manufactured and developed by Pfizer/Wyeth, to
treat acute myelogenous leukemia. The drug was subsequently withdrawn in June 2010, leaving
only two antibody drug conjugates in the market. The two drugs marketed for ADCs are
Brentuximab vedotin and Trastuzumab emtansine, developed and manufactured by Seattle
Genetics and Millennium/Takeda and Genentech and Roche, respectively. Around 45 antibody
drug conjugates molecules are under clinical trials, with the preclinical pipeline expanding at a
high rate. Of all the 45 molecules, around 25% are under Phase II or Phase III of development.
Frequently used cytotoxins for antibody drug conjugates under trials include auristatin,
calicheamicin, maytansine and duocarmycin. Auristatin is the dominant compound accounting
for over 50% of antibody drug conjugates in clinical development. Roche has 10 compounds
under clinical trials, and this is the most developed pipeline of antibody drug conjugates.
Globally, 70%-80% of antibody drug conjugates manufacturing is currently outsourced. There are
limited number of contract manufacturers that have high-end manufacturing equipment for
development of cytotoxins.
Report includes chapters which deeply display the following deliverable about industry :
• Antibody Drug Conjugates Market Research Objective and Assumption
• Antibody Drug Conjugates Market Purview - Report Description, Executive Summary, and Coherent
Opportunity Map (COM)
• Antibody Drug Conjugates Market Dynamics, Regulations, and Trends Analysis - Market Dynamics,
Regulatory Scenario, Industry Trend, Merger and Acquisitions, New system Launch/Approvals, Value
Chain Analysis, Porter’s Analysis, and PEST Analysis
• Global Antibody Drug Conjugates Market, By Regions
• Antibody Drug Conjugates Market Competition by Manufacturers including Production, Share,
Revenue, Average Price, Manufacturing Base Distribution, Sales Area and Product Type.
• Antibody Drug Conjugates Market Manufacturers Profiles/Analysis including Company Basic
Information, Manufacturing Base and Its Competitors.
• Antibody Drug Conjugates Market Manufacturing Cost Analysis including Key Raw Materials and
Key Suppliers of Raw Materials.
• Industrial Chain, Sourcing Strategy and Downstream Buyers including Upstream Raw Materials
Sourcing and Downstream Buyers
• Marketing Strategy Analysis, Distributors/Traders including Marketing Channel, Market Positioning
and Distributors/Traders List.
• Market Effect Factors Analysis including Technology Progress/Risk, Consumer Needs/Customer
Preference Change and Economic/Political Environmental Change.
• Antibody Drug Conjugates Market Forecast including Production, Consumption, Import and Export
Forecast by Type, Applications and Region.
• Research Findings and Conclusion
Large number of clinical trial molecules in pipeline to boost growth of antibody drug
conjugates market
Key players operating the antibody drug conjugates market include Hoffmann-La
Roche Ltd, Seattle Genetics, Takeda, ImmunoGen Inc, Pfizer Inc., Sanofi, AbbVie Inc,
Cellldex Therapeutics, Synthon, and Progenics Pharmaceuticals.
Inquire Here Before Purchase:
https://www.coherentmarketinsights.com/insight/talk-to-analyst/181
About Coherent Market Insights
Coherent Market Insights is a prominent market research and consulting firm offering action-ready
syndicated research reports, custom market analysis, consulting services, and competitive analysis
through various recommendations related to emerging market trends, technologies, and potential
absolute dollar opportunity.
Contact Us
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: [email protected]

Antibody drug conjugate is a significant class of highly potent bio drugs envisioned as a broad therapy for treatment of cancer

Download Report